Join Medicilon at AAPS 2024 PHarmSCi 360

Troubled by your current problems with drug discovery? Meet Medicilon at AAPS 2024 PHarmSCi 360! It kicks off on October 20 in Salt Lake City. Medicilon team will be present in person at booth#1526! Maybe Medicilon can help you solve your current problem and become a partner of choice! Medicilon is continuedly advancing its technology platforms constantly, collaborating closely with our global clients to deliver demanding and innovative novel drug research.

We are happy to meet you in person to discuss how our services and capabilities would support your current research needs and expedite your drug discovery and development programs.

Date: October 20-23, 2024

Location: Salt Palace Convention Center, Salt Lake City, UT

Medicilon Booth #1526

AAPS 2024 PHarmSCi 360

Founded in 1986, the American Association of Pharmaceutical Scientists (AAPS) is a professional, scientific organization of approximately 7,000 individual members and over 10,000 actively participating stakeholders employed in academia, industry, government, and other pharmaceutical science related research institutes worldwide. Their mission is  to advance the capacity of pharmaceutical scientists to develop products and therapies that improve global health. Their vision is advancing the pharmaceutical sciences to drive prevention and cures.

AAPS2024 Highlights

❖Discovery and Basic Research

❖Preclinical, Clinical and Translational Sciences

❖Bioanalytics

❖Manufacturing and Analytical Characterization

❖Formulation and Delivery

❖Career Development

Medicilon

Medicilon is a leading global integrated pharmaceutical R&D service contract research organization (CRO), providing a full range of one-stop preclinical R&D services, in compliance with Chinese and international regulatory filing standards, to pharmaceutical companies and research institutions world-wide. With our experience in serving domestic and foreign biomedical industries, we have built an integrated platform covering key technologies in drug discovery, pharmaceutical research, and preclinical research, to provide a comprehensive preclinical R&D service for the global biomedical industry.

20 Years of Excellence

500+ IND Approved by FDA, NMPA, EMA, and TGA

2000+ Active Clients Worldwide

2600+ Scientists & Research Staff

85,000+ m² Lab Space

At Medicilon, we are dedicated to support our clients develop their research and discovery programs from initial concept through the IND filing phase. Our services span across medicinal chemistry, biology, API, CMC, formulation, and preclinical studies. We provide flexible business models, including stand-alone Fee for Services (FFS) and fully integrated FTE services. In addition, our facilities are GLP/GMP compliant, US-FDA, China NMPA and AAALAC accredited. All study reports can be presented in SEND format, supporting dual filing of IND applications in the US, EU, and China.

Medicilon Innovative R&D Technology Service Platforms

❖PROTAC

PROTACs offer a fast and reversible chemical knoc-down approach to control protein function in the cell. The impact of the PROTAC platform has changed the landscape of drug discovery and development. Medicilon’s PROTAC drug discovery technology platform covers many of the popular target protein ligands. We have established an extensive collection of bifunctional linkers. Together with our expanding E3 ubiquitin ligase binder library, we can efficiently synthesize highly active PROTAC bispecific small molecules, which have the potential to significantly facilitate the drug development process. In addition, Medicilon has established as well as improved the PROTAC biological screening and testing platform throughout the pre-clinical stages. Medicilon’s strong technical expertise and flexible service models allow individualized and customized projects ranging from sole chemical synthesis to in vitro and/or in vivo service, and to more comprehensive integrated package support.  As of the end of June 2024, Medicilon has successfully assisted in the clinical approval of 6 PROTAC drugs (2 approved by FDA and NMPA) and has 20+ PROTAC projects under development.

❖ADC

We specialize in Antibody-Drug Conjugates (ADCs), a revolutionary approach to cancer treatment. Our services encompass the entire ADC development process, including:

• ADC Chemistry: Payload and linker R&D, antibody-drug conjugation

• In Vitro Evaluation: Binding assays, internalization, cell cycle & apoptosis analysis, bystander effect studies

• In Vivo Evaluation: Pharmacodynamics, pharmacokinetics, toxicology studies

Our team has successfully supported 28 IND approvals for ADC therapies, underscoring our leadership in this field.

❖Antibody

With the development of antibody technology, antibody now presents a good development prospect. While major companies are deploying antibody product research and development, they also pay great attention to what needs to be paid attention to and considered in the biological analysis of antibody. Regulations and technical points. The Pharmaceutical Analysis Department of Medicilon Biotechnology is committed to tailoring Case by Case biological analysis methods for customers. As of April 2024, Medicilon has successfully assisted clients on the IND approval of 33 antibody drugs and has multiple antibody projects on going.

❖Nucleic Acid Drug

Medicilon nucleic acid drug R&D platform provides an integrated and comprehensive solution that covers drug discovery, CMC and preclinical research services. Oriented with a rigorous scientific approach, an open-minded teamwork spirit and state-of-the-art equipment, our integrated solution will help clients and partners to fulfil their research and development mission for cutting-edge and innovative nucleic acid drugs. Our service platforms include nucleic acid drug discovery, screening and preclinical research services of pharmacology, DMPK and toxicity study for both pharmaceutical companies and academic research institutions. Attributed by its fast and intuitive design of base sequences, the development of nucleic acid drugs is featured with simple materials, convenient preparation processes and affordable production costs, which will greatly shorten the drug development cycle, making it possible to customize individual treatment plans. Hence, it offers a feasible solution for rare diseases and other problems currently plagued.

❖Peptide

In the research and development of peptide drugs, the many characteristics of peptides have caused difficulties and challenges in the analysis process. In the analysis of peptide biotechnology drugs, Medicilon Biotechnology Drug Analysis Department flexibly uses ELISA, ECL, TRFIA, CLIA, IF, IP, CoIP, qPCR, FACS, ELISpot, enzymology and other methods to support cutting-edge biology Drugs such as proteins, antibodies (monoclonal antibodies, bi- or multispecific antibodies, antibody fragments), ADCs, peptides, nucleic acids, vaccines and cell gene therapy and other drugs in the early development, preclinical and clinical stages of PK/TK/Immunogenicity (Total ADA& Nab)/Biomarker&Cytokine and other research evaluation.

❖mRNA Vaccine Bioanalysis Platform

Medicilon has provided comprehensive support and services for the safety and effectiveness evaluation of various new drugs and vaccines, specifically the research of LNP-mRNA drugs and vaccines, accumulating rich experience. Hence we establish the bioanalysis platform for mRNA vaccines.

❖Cell & Gene Therapy

Cell & Gene therapy has developed rapidly in recent years, providing the possibility of curing many difficult-to-treat cancers. With the rapid development of gene transduction and gene modification technology, delivery vector system, cell culture technology and other fields, gene therapy has made a breakthrough, provide a better solution, concept and idea for intractable diseases (especially rare genetic diseases). Medicilon has established a one-stop research platform for the preclinical R&D of cell & gene immunotherapies, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK. Using a wealth of animal models and a variety of advanced analysis techniques, comprehensively considering the characteristics of different research projects, Medicilon has completed multiple preclinical projects for clients worldwide.

❖AI R&D Innovation

As the first CRO stock on the Sci-tech Innovation Board, Medicilon is one of the companies that pay attention to AI technology in the industry at the beginning.  Currently, Medicilon uses deep neural network machine learning technology to construct a BTK inhibitor drug design model.  Medicilon also commits to establishing a molecular design and screening platform for BTK inhibitor drugs, launching “CRO+AI” to accelerate the development of new drugs.

#AAPS2024 #PHARMSCI360 #PCC #preclinical #technologyplatform #candidate

Meet with Medicilon

Subject丨AAPS 2024

Company *

Name *

Work Email *

Title*

Verification Code